| 26.98 -0.01 (-0.04%) | 03-09 16:01 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 31.6 | 1-year : | 36.91 |
| Resists | First : | 27.05 | Second : | 31.6 |
| Pivot price | 26.95  |
|||
| Supports | First : | 26.92 |
Second : | 26.84 |
| MAs | MA(5) : | 26.97 |
MA(20) : | 26.95 |
| MA(100) : | 26.72 |
MA(250) : | 19.2 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 84.2 |
D(3) : | 69 |
| RSI | RSI(14): 61  |
|||
| 52-week | High : | 27.05 | Low : | 7.67 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ MYOV ] has closed below upper band by 18.8%. Bollinger Bands are 94.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 80 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 27.04 - 27.18 | 27.18 - 27.29 |
| Low: | 26.66 - 26.81 | 26.81 - 26.93 |
| Close: | 26.77 - 26.99 | 26.99 - 27.18 |
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Sumitovant Biopharma Ltd.
Fri, 10 Mar 2023
Sumitovant Biopharma Completes Acquisition of Myovant Sciences - PR Newswire
Sun, 23 Oct 2022
Sumitovant Biopharma, Sumitomo Pharma, and Myovant Sciences Enter into Definitive Agreement - PR Newswire
Mon, 09 May 2022
Myovant Sciences and Accord Healthcare, Ltd. Enter into - GlobeNewswire
Sun, 02 Jan 2022
Myovant Stock: Catalysts Powering More Upsides (NYSE:MYOV) - Seeking Alpha
Tue, 05 Jan 2021
Myovant Sciences Announces U.S. Availability of ORGOVYX™ for the Treatment of Advanced Prostate Cancer - GlobeNewswire
Mon, 28 Dec 2020
Why This Recently Approved Prostate Cancer Treatment Could Be Huge for Myovant - 24/7 Wall St.
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 97 (M) |
| Shares Float | 51 (M) |
| Held by Insiders | 48.6 (%) |
| Held by Institutions | 56.2 (%) |
| Shares Short | 8,390 (K) |
| Shares Short P.Month | 6,740 (K) |
| EPS | -1.92 |
| EPS Est Next Qtrly | -0.44 |
| EPS Est This Year | -1.45 |
| EPS Est Next Year | -1.21 |
| Book Value (p.s.) | -5.75 |
| Profit Margin | -48.5 % |
| Operating Margin | -38.8 % |
| Return on Assets (ttm) | -18.3 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 84 % |
| Gross Profit (p.s.) | 0.74 |
| Sales Per Share | 3.89 |
| EBITDA (p.s.) | -1.5 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -270 (M) |
| Levered Free Cash Flow | -149 (M) |
| PE Ratio | -14.06 |
| PEG Ratio | 0 |
| Price to Book value | -4.7 |
| Price to Sales | 6.92 |
| Price to Cash Flow | -9.73 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|